+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected



Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected



Lancet 350(9093): 1729-1733



Cytomegalovirus (CMV) disease is a frequent cause of serious morbidity after solid-organ transplantation. The prophylactic regimens used to prevent CMV infection and disease have shown limited benefit in seronegative recipients. We studied the safety and efficacy of oral ganciclovir in the prevention of CMV disease following orthotopic liver transplantation. Between December, 1993, and April, 1995, 304 liver-transplant recipients were randomised to receive oral ganciclovir 1000 mg or matching placebo three times a day. Seronegative recipients of seronegative livers were excluded. Study drug was administered as soon as the patient was able to take medication by mouth (no later than day 10) until the 98th day after transplantation. Patients were assessed at specified times throughout the first 6 months after surgery for evidence of CMV infection, CMV disease, rejection, opportunistic infections, and possible drug toxicity. The Kaplan-Meier estimate of the 6-month incidence of CMV disease was 29 (18.9%) of 154 in the placebo group, compared with seven (4.8%) of 150 in the ganciclovir group (p < 0.001). In the high-risk group of seronegative recipients (R-) of seropositive livers (D+), incidence of CMV disease was 11 (44.0%) of 25 in the placebo group, three (14.8%) of 21 in the ganciclovir group (p = 0.02). Significant benefit was also observed in those receiving antibodies to lymphocytes, where the incidence of CMV disease was 12 (32.9%) of 37 in the placebo group and two (4.6%) of 44 in the ganciclovir group (p = 0.002). Oral ganciclovir reduced the incidence of CMV infection (placebo 79 [51.5%] of 154; ganciclovir 37 [24.5%] of 150; p < 0.001) and also reduced symptomatic herpes-simplex infections (Kaplan-Meier estimates: placebo 36 [23.5%] of 154; ganciclovir five [3.5%] of 150; p < 0.001). Oral ganciclovir is a safe and effective method for the prevention of CMV disease after orthotopic liver transplantation.

(PDF emailed within 1 workday: $29.90)

Accession: 047168155

Download citation: RISBibTeXText

PMID: 9413463


Related references

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet (North American Edition) 350(9093): 1729-1733, Dec 13, 1997

Efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 163, 1996

Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Transplantation Proceedings 26(1): 173-174, 1994

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 75(2): 229-233, 2003

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. American Journal of Transplantation 4(4): 611-620, 2004

Randomized controlled trial of oral ganciclovir versus intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in CMV-seronegative liver transplant recipients willi CMV-seropositive donors. International Journal of Infectious Diseases 6(Supplement 2): 2S26-2S27, 2002

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77(2): 305-308, 2004

Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 70(5): 717-722, 2000

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. New England Journal of Medicine 334(23): 1491-1497, 1996

Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group. Aids 9(5): 471-477, 1995

Oral ganciclovir monotherapy in the prevention of cytomegalovirus disease in liver transplant recipients. Gastroenterology 116(4 PART 2): A715, 1999

Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. Transplant Infectious Disease 2(1): 2-10, 2001

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. Transplantation 66(12): 1780-1786, 1999

Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transplant Infectious Disease 2(3): 112-117, 2001

Efficacy and cost-efficacy of preemptive oral ganciclovir for the prevention of CMV disease in liver transplant recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 275, 2000